Advertisement

Topics

Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder

07:00 EDT 21 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
— Company Expects to Complete Submission for Fast Track Designated Medicine by Year-End 2017 — Alkermes plc (NASDAQ:ALKS) today announced the initiation of its rolling submission of a New Drug Application (NDA) to...

Other Sources for this Article

Alkermes:
For Investors:
Eva Stroynowski, +1 781-609-6823
or
Sandy Coombs, +1 781-609-6377
or
For Media:
Jennifer Snyder, +1 781-609-6166

NEXT ARTICLE

More From BioPortfolio on "Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...